akash
☆    

India,
2019-02-23 08:39
(736 d 02:51 ago)

Posting: # 19967
Views: 3,731
 

 Why BE testing use 90 CI [General Sta­tis­tics]

Why Bioequivalence testing makes use of the 90 CI why not 95 CI which gives more accuracy?


Edit: Category changed; see also this post #1. Please follow the Forum’s Policy[Helmut]
ElMaestro
★★★

Denmark,
2019-02-23 10:18
(736 d 01:12 ago)

@ akash
Posting: # 19968
Views: 3,342
 

 Why BE testing use 90 CI

Hi Akash,

» Why Bioequivalence testing makes use of the 90 CI why not 95 CI which gives more accuracy?

More accuracy, what does that mean?

We have some more or less empirically justified limits of 80.00%-125.00%.
And we want a 5% risk of making the wrong conclusions in the sense of regulatory (patient's) risk; in practice this means we adopt a policy of a 5% risk of approving a product that is not BE. This is where the 90% CI comes into the equation. There is a (not more than) 5% risk associated with it (1-2*alpha).

A 95% CI would be less risky, ie. up to 2.5% chance of approving a non-BE product. Why would we want that, then alpha=5% seems to work just fine?

Pass or fail!
ElMaestro
Ohlbe
★★★

France,
2019-03-03 23:07
(727 d 12:23 ago)

@ ElMaestro
Posting: # 19992
Views: 3,191
 

 Why BE testing use 90 CI

Dear Akash,

» This is where the 90% CI comes into the equation. There is a (not more than) 5% risk associated with it (1-2*alpha).

My understanding of the reason why: the true T/R ratio cannot be at the same time lower than 0.8 and higher than 1.25. So even if you test the lower limit with a 5 % risk, and the higher limit with a 5 % risk, the overall risk still remains 5 % for the patients, not 10 %.

Regards
Ohlbe
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2019-03-04 01:20
(727 d 10:10 ago)

@ Ohlbe
Posting: # 19996
Views: 3,177
 

 one-sided / two-sided

Hi Ohlbe,

» […] So even if you test the lower limit with a 5 % risk, and the higher limit with a 5 % risk, the overall risk still remains 5 % for the patients, not 10 %.

Correct.

@Akash: Maybe you were confused by one-sided superiority testing in phase III (which is performed at an α-level of 5%). In other words, if patients are treated with the originator’s product, there is a 5% risk that it does not perform better (more efficient and/or safer) than placebo.
If we would test for BE at the 2.5% level (95% CI) we would be overly strict and at the same time gain absolutely nothing in terms of the patient’s risk.

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
ElMaestro
★★★

Denmark,
2019-03-04 09:04
(727 d 02:26 ago)

@ Helmut
Posting: # 19997
Views: 3,181
 

 one-sided / two-sided

Hi Hötzi,


» In other words, if patients are treated with the originator’s product, there is a 5% risk that it does not perform better (more efficient and/or safer) than placebo.

There is no more than a 5% risk of approving the test product (=concluding superiority) if the test product is not superior.

» If we would test for BE at the 2.5% level (95% CI) we would be overly strict and at the same time gain absolutely nothing in terms of the patient’s risk.

The patient's risk would be halved (max 2.5% chance of approving a non-BE product; CIs would get wider).

Pass or fail!
ElMaestro
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2019-03-04 11:25
(727 d 00:05 ago)

@ ElMaestro
Posting: # 19998
Views: 3,137
 

 one-sided / two-sided

Hi ElMaestro,

sure. What I meant is: If a drug-naïve patient is treated with the originator’s product, the risk is 5%. With a 90% in BE the risk is also 5%.

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Activity
 Admin contact
21,357 posts in 4,459 threads, 1,492 registered users;
online 9 (0 registered, 9 guests [including 2 identified bots]).
Forum time: Sunday 11:30 CET (Europe/Vienna)

Facts are the air of scientists.
Without them you can never fly.    Linus Pauling

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5